🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

28 recruiting trials

for IDH1-Mutated Malignancies

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations NCT07032727Phase 22 sites📍 Miami📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib, Cladribine (CLAD), Venetoclax, Gilteritinib, Ruxolitinib A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. NCT06566742Phase 22 sites📍 Miami📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies NCT06668584Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant NCT06543381Phase 12 sites📍 Duarte📍 Cleveland City of Hope Medical Center · Tests: Biospecimen Collection, Olutasidenib Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax NCT07471841Phase 21 site📍 Winston-Salem Timothy Pardee · Tests: Olutasidenib, Azacitidine (AZA) a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia NCT07007949Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Ivosidenib combined with venetoclax and azacitidine, Ivosidenib combined with venetoclax and azacitidine An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. NCT05907057Phase 315 sites📍 Vienna📍 Wels📍 Marseille Servier Affaires Médicales · Tests: Ivosidenib 500mg Oral Tablet, Azacitidine Chronic CED of TPT for Recurrent Malignant Glioma NCT06666712Phase 11 site📍 New York Jeffrey N. Bruce · Tests: Topotecan Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent NCT07304011Phase 22 sites📍 Orange📍 Sacramento University of California, Davis · Tests: Azacitidine, Olutasidenib A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment NCT07006688Phase 120 sites📍 Atlanta📍 Columbus📍 Houston Servier Bio-Innovation LLC · Tests: Ivosidenib Oral Tablet Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies NCT03471260Phase 1, Phase 24 sites📍 Boston📍 Cleveland📍 Portland M.D. Anderson Cancer Center · Tests: Azacitidine, Ivosidenib, Venetoclax Diagnostic and Therapeutic Targets in Cartilaginous Tumours NCT07315542n/a1 site📍 Brno St. Anne's University Hospital Brno, Czech Republic · Tests: Tumour tissue analysis, Molecular validation, Liquid biopsy analysis 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations NCT05588141Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Zotiraciclib Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy NCT07075016Phase 3119 sites📍 Feldkirch📍 Salzburg📍 Vienna Stichting Hemato-Oncologie voor Volwassenen Nederland · Tests: Venetoclax 400, Placebo A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia NCT06387069Phase 353 sites📍 Hefei📍 Hefei📍 Hefei Hutchmed · Tests: HMPL-306 Regimen, Salvage Chemotherapy Regimen Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation NCT02074839Phase 130 sites📍 Birmingham📍 Phoenix📍 Duarte Institut de Recherches Internationales Servier · Tests: AG-120 Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation NCT06291987Phase 12 sites📍 Chicago📍 Milwaukee University of Chicago · Tests: Ivosidenib, Ruxolitinib Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation NCT06717958Phase 217 sites📍 Aachen📍 Chemnitz📍 Dresden Technische Universität Dresden · Tests: Ivosidenib 250 MG (milligram) Ivosidenib as Post-HSCT Maintenance for AML NCT06707493Phase 27 sites📍 Atlanta📍 Kansas City📍 Boston Massachusetts General Hospital · Tests: Ivosidenib, Placebo Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen NCT06127407Phase 3115 sites📍 Los Angeles📍 Santa Monica📍 Aurora Servier Bio-Innovation LLC · Tests: Ivosidenib 500mg, Placebo Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies NCT07486713Phase 42 sites📍 Orange📍 New York Rigel Pharmaceuticals · Tests: Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS NCT07607418Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Ivosidenib ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer NCT07151118n/a1 site📍 Seongnam-si CHA University · Tests: Blood Sampling for ctDNA Analysis Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC NCT07142226n/a1 site📍 Seongnam-si CHA University · Tests: Circulating Tumor DNA (ctDNA) Testing (ctDNA-based Next-Generation Sequencing (NGS)) Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy NCT06782542Phase 21 site📍 Miami Justin Watts, MD · Tests: Olutasidenib, Venetoclax, Azacitidine CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04493164Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study NCT06607302n/a19 sites📍 Augsburg📍 Bad Liebenwerda📍 Bad Mergentheim iOMEDICO AG Study of Olutasidenib and Temozolomide in HGG NCT06161974Phase 220 sites📍 Aurora📍 Washington D.C.📍 Miami Rigel Pharmaceuticals · Tests: Olutasidenib + TMZ
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy